Urothelial Cancer Genomics

Bladder cancer hits Yorkshire harder than anywhere else in the UK, and it is the most expensive cancer to treat. This programme will scan the complete DNA of hundreds of bladder tumours to find the genetic changes that drive the disease. The problem is that doctors currently lack reliable genetic tests to predict which bladder cancers will turn aggressive or which drugs a patient will respond to. Without that information, treatment decisions are made largely on tumour stage and grade—blunt tools that miss crucial biological differences. The Yorkshire research team has already found that these tumours contain a wealth of unexplored genomic information. They will now map DNA copy number changes and mutations across a large panel of tumour samples, then develop simple, clinic-ready assays that can flag the most informative genetic markers. If successful, this work could give clinicians a practical tool to personalise treatment—sparing some patients from harsh chemotherapy that won't help them, while steering others toward more aggressive therapy early. It could also reveal new molecular targets for drug development. The immediate impact is on medical diagnostics and the treatment pathway for bladder cancer, a disease that quietly consumes enormous healthcare resources.